![]() ![]() 2 Moreover, 5 of 6 patients achieved durable partial responses per modified Response Assessment in Neuro-Oncology criteria, and 1 patient experienced progressive disease due to distant failure despite maintained target lesion control. Previously reported data from the expansion arm showed that at a median of 15 months on the study, 5 of 6 patients (83%) were still alive. This CR took about 12 months of therapy to achieve, underlining the importance of mature data to fully evaluate the power of NOX-A12-based therapy.” “It is very encouraging to see 1 patient achieve no detectable tumor and 2 patients coming extremely close to CR, achieving a reduction in tumor size of more than 99%. “We are very pleased to report this highly positive update from the expansion arm of our GLORIA clinical trial evaluating our lead asset NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma,” Aram Mangasarian, chief executive officer of TME Pharma, stated in a news release. Furthermore, 2 patients achieved more than 99% tumor shrinkage, resulting in a CR or near-CR rate of 50%. 1Īmong 6 evaluable patients in the expansion arm, 1 patient experienced a complete response (CR) after previously having a best response of 89.9% tumor shrinkage. The addition of the CXCL12 inhibitor NOX-A12 to standard-of-care (SOC) radiotherapy and bevacizumab (Avastin) elicited responses when used as first-line treatment in patients with glioblastoma, according to updated data from the expansion arm of the phase 1/2 GLORIA trial (NCT04121455).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |